TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37417824
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors
Study: 37417824
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin receptor-neprilysin inhibitors+beta-blocker+mineralocorticoid receptor antagonist)
Study: 37417948
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, tumor bed, and residual contrast enhancements, with concomitant Temozolomide for 6 months.
Study: 37417948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of 60 Gy with concomitant Temozolomide for 6 months.
Study: 37417948
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy.
Study: 37417948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of 60 Gy.
Study: 37417948
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Study: 37417948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Study: 37417970
Drug: Combined Platelet-Rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Platelet-Rich Plasma Noncrosslinked Hyaluronic Acid Injections
Study: 37418059
Drug: Personal Analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal Analgesic Sufficiency Status (PASS) measured by pre-tetanus-induced ANI variation
Study: 37418059
Drug: Sevoflurane and
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane and increased effect-site concentrations of remifentanil (2, 4, 6 ng/ml)
Study: 37418263
Drug: Erythropoietin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin treatment (1000 U/kg/dose on days 1, 2, 3, 4, and 7)
Study: 37418498
Drug: iCARE Nigeria
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCARE Nigeria HIV treatment support intervention (peer navigation and SMS text message medication reminders)
Study: 37418583
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of injectable-platelet-rich fibrin (i-PRF) and type-1 collagen particles applied to the defect in adjunct to periapical surgery (n=19)
Study: 37418643
Drug: Targeted molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted molecular therapy
Study: 37418685
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and lenalidomide (R2) combination therapy: 20 mg oral lenalidomide from days 2 to 22 and IV rituximab 375 mg/m2 on day 1 for a maximum of 6 cycles.
Study: 37418685
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of lenalidomide at 10 mg/d from days 1 to 21 for every 28 days for a total of 12 cycles after achieving partial or complete response.
Study: 37419129
Drug: Alum-adjuvanted 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted 12 μg
Study: 37419129
Drug: Alum-adjuvanted 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted 48 μg
Study: 37419129
Drug: Alum-adjuvanted 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted 90 μg
Study: 37419129
Drug: Non-adjuvanted 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted 12 μg
Study: 37419144
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg added to background multidrug therapy for 12 months
Study: 37419144
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg
Study: 37419144
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS) with clofazimine or clofazimine plus azithromycin
Study: 37419633
Drug: treatment-as-usual waitlist
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual waitlist control group
Study: 37419638
Drug: Ivermectin mass
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin mass drug administration (MDA) combined with artemisinin-based combination therapy (ACT)
Study: 37420006
Drug: IL-1β-neutralizing antibody
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1β-neutralizing antibody canakinumab
Study: 37420013
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for dizziness
Study: 37420013
Drug: Falls and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falls and treatment for dizziness
Study: 37420013
Drug: Dizziness treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dizziness treatment
Study: 37420268
Drug: Digital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital therapy (Playball)
Study: 37420268
Drug: Non-digital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-digital therapy
Study: 37420274
Drug: PF-06804103 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06804103 3.0 mg/kg Q3W
Study: 37420274
Drug: PF-06804103 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06804103 4.0 mg/kg Q3W
Study: 37420274
Drug: PF-06804103 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06804103 (all doses)
Study: 37421291
Drug: TEER with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEER with MitraClip plus guideline-directed medical therapy (GDMT)
Study: 37421320
Drug: In-laboratory titration
Normalized name: A & L Laboratories Protect
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-laboratory titration polysomnography (tPSG)
Study: 37421604
Drug: Crovalimab (C5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab (C5 inhibitor), loading doses (one intravenous, four subcutaneous) and subsequent every-4-weeks subcutaneous maintenance doses per weight-based tiered-dosing schedule.
Study: 37421604
Drug: Crovalimab (C5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab (C5 inhibitor)
Study: 37422079
Drug: Rilematovir 500
Normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilematovir 500 mg
Study: 37422079
Drug: Rilematovir 80
Normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilematovir 80 mg
Study: 37422241
Drug: 3-L polyethylene
Normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-L polyethylene glycol (PEG)
Study: 37422518
Drug: SCTV01E (30 µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTV01E (30 µg)
Study: 37422518
Drug: SCTV01C (20 µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTV01C (20 µg)
Study: 37422518
Drug: BNT162b2 (20 µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (20 µg)
Study: 37422666
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous unfractionated heparin (UFH) therapy
Study: 37422666
Drug: Subcutaneous low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low-molecular-weight heparin (LMWH) injection
Study: 37422688
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m², venetoclax, and pevonedistat
Study: 37422772
Drug: BAY1128688 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 3 mg once daily
Study: 37422772
Drug: BAY1128688 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 10 mg once daily
Study: 37422772
Drug: BAY1128688 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 30 mg once daily
Study: 37422772
Drug: BAY1128688 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 30 mg twice daily
Study: 37422772
Drug: BAY1128688 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 60 mg twice daily
Study: 37423228
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg IV every 3 weeks)
Study: 37423228
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (vinorelbine or gemcitabine, dosing per local label)
Study: 37423231
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg once daily)
Study: 37423623
Drug: CAB+RPV long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB+RPV long-acting (LA) administration
Study: 37423647
Drug: Active conventional
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conventional therapy
Study: 37423717
Drug: Mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 300 mg monthly for 3 months
Study: 37423717
Drug: Mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 300 mg monthly for 6 months (mepo/mepo)
Study: 37423717
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Mepolizumab 100 mg monthly for 3 months (pbo/mepo)
Study: 37423801
Drug: H-SC (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-SC (600 mg fixed-dose)
Study: 37423834
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg i.v. dissolved in 0.9% saline 150 ml
Study: 37423834
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline 150 ml)
Study: 37424311
Drug: Legume group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legume group (20% TPI, 200 g RPM per week)
Study: 37424311
Drug: Meat group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat group (25% TPI, 760 g RPM per week)
Study: 37424700
Drug: DLBS3233 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS3233 (100 mg once per day)
Study: 37424700
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR (750 mg twice per day)
Study: 37424700
Drug: DLBS3233 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS3233 (100 mg once per day) + Metformin XR (750 mg twice per day)
Study: 37425298
Drug: TTV load
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTV load and QF-Mg
Study: 37426086
Drug: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment
Study: 37426430
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cells (MSC) infusion at 6 and 7 weeks post-transplantation
Study: 37426430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MSC infusion)
Study: 37427566
Drug: Repeated SI
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated SI (transplant to the duodenum twice)
Study: 37428030
Drug: Intervention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention to reduce cardiovascular risk; details on dosage and duration not available.
Study: 37428347
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus Aromatase Inhibitor (AI)
Study: 37428347
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitor (AI) monotherapy
Study: 37428480
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg; maximum dose, 1000 mg)
Study: 37428480
Drug: Cenicriviroc (300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (300-mg loading dose followed by 150 mg twice per day)
Study: 37428504
Drug: Deprescribing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deprescribing intervention (physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone for a maximum of 180 days)
Study: 37428681
Drug: Post-opioid administration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-opioid administration
Study: 37428866
Drug: Supplemental ready-to-use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental ready-to-use therapeutic food (RUTF) with moderate-dose hydroxyurea therapy (20 mg/kg per day)
Study: 37428866
Drug: Supplemental ready-to-use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental ready-to-use therapeutic food (RUTF) without moderate-dose hydroxyurea therapy
Study: 37429122
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation (VNS) titration according to Group A protocol
Study: 37429122
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation (VNS) titration according to other protocols (Group B and Group C)
Study: 37429122
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation (VNS) titration (all groups)
Study: 37429302
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months
Study: 37429622
Drug: 0.15% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine injected, 1 mL at a time, up to 1.0 mL.kg
Study: 37429622
Drug: Local anesthetics
Normalized name: LOCAL ANESTHETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetics of 0.223, 0.591, and 0.797 mL.kg
Study: 37429637
Drug: C reactive
Normalized name: C reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C reactive protein >3 mg/L
Study: 37429637
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume index >34 mL/m²
Study: 37429687
Drug: Ciclosporin (CsA)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CsA) as first-line treatment for atopic dermatitis.
Study: 37429687
Drug: Ciclosporin (CsA)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CsA) therapy (for patients already receiving or who have received CsA).
Study: 37429923
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily)
Study: 37429923
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks) + anti-CTLA-4 quavonlimab (25 mg every 6 weeks)
Study: 37429923
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks) + anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks)
Study: 37430077
Drug: Oral zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zeaxanthin (Zx) 20 mg daily for ≥ 5 years
Study: 37430233
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose lipid emulsion
Study: 37430233
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose lipid emulsion (half of the usual dose)
Study: 37430359
Drug: Intraoperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative goal-directed fluid therapy (GDFT)
Study: 37430359
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid therapy (RFT)
Study: 37430375
Drug: High daily
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High daily urinary output (> 436 ml/d)
Study: 37431406
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy for Health in Adolescents (AHEAD)
Study: 37432025
Drug: Single-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L
Study: 37432025
Drug: Single-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 800 L
Study: 37432025
Drug: Single-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L in Scale B
Study: 37432025
Drug: Single-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 500 L
Study: 37432311
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for ≥2 years
Study: 37432430
Drug: Cytisinicline, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline, 3 mg, 3 times daily for 6 weeks
Study: 37432430
Drug: Cytisinicline, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline, 3 mg, 3 times daily for 12 weeks
Study: 37432430
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times daily for 6 weeks
Study: 37432430
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times daily for 12 weeks
Study: 37432723
Drug: CBT-txt (SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-txt (SMS text message-delivered cognitive behavioral therapy)
Study: 37432736
Drug: ATG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG plus granulocyte colony-stimulating factor (ATG/G-CSF)
Study: 37433021
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens of Ad26.RSV.preF and RSV preF protein
Study: 37433021
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen comprising Ad26.RSV.preF and RSV preF protein
Study: 37433173
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/FA 0.4 mg tablet daily (A group)
Study: 37433173
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/FA 0.8 mg tablet daily (B group)
Study: 37433173
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily (C group, control group)
Study: 37433729
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) administered at a rate of 0.1 µg/kg/hour for 48 hours during general anaesthesia induction.
Study: 37433729
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered at the same rate as DEX in the control group.
Study: 37433734
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of bupivacaine
Study: 37434165
Drug: High-dose acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acupuncture (HA, 7 times each chemo-cycle for 3 cycles)
Study: 37434165
Drug: Low-dose acupuncture
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acupuncture (LA, 3 times each chemo-cycle for 3 cycles)
Study: 37434165
Drug: High-dose acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acupuncture (HA)
Study: 37434165
Drug: Low-dose acupuncture
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acupuncture (LA)
Study: 37434306
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (ET)
Study: 37434306
Drug: Early discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early discontinuation model
Study: 37435073
Drug: Bivalent norovirus
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
Study: 37435299
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (medication reconciliation or MedRec) without MedSafer reports
Study: 37435777
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulation (no OAC)
Study: 37436730
Drug: Any mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any mental health disorder/psychotropic prescription
Study: 37436730
Drug: Socioeconomic difficulties
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socioeconomic difficulties associated with mental health disorder/psychotropic prescriptions
Study: 37436797
Drug: Antipneumococcal antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipneumococcal antibody titers
Study: 37437144
Drug: BRAF-MEK inhibitor
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF-MEK inhibitor combination vemurafenib-cobimetinib